全文获取类型
收费全文 | 32942篇 |
免费 | 2213篇 |
国内免费 | 1283篇 |
专业分类
耳鼻咽喉 | 250篇 |
儿科学 | 355篇 |
妇产科学 | 824篇 |
基础医学 | 7397篇 |
口腔科学 | 517篇 |
临床医学 | 2130篇 |
内科学 | 4903篇 |
皮肤病学 | 530篇 |
神经病学 | 1101篇 |
特种医学 | 1407篇 |
外国民族医学 | 3篇 |
外科学 | 1518篇 |
综合类 | 4208篇 |
预防医学 | 2455篇 |
眼科学 | 241篇 |
药学 | 3327篇 |
2篇 | |
中国医学 | 755篇 |
肿瘤学 | 4515篇 |
出版年
2023年 | 372篇 |
2022年 | 490篇 |
2021年 | 740篇 |
2020年 | 858篇 |
2019年 | 785篇 |
2018年 | 676篇 |
2017年 | 878篇 |
2016年 | 979篇 |
2015年 | 1143篇 |
2014年 | 1639篇 |
2013年 | 2230篇 |
2012年 | 1537篇 |
2011年 | 1882篇 |
2010年 | 1539篇 |
2009年 | 1655篇 |
2008年 | 1635篇 |
2007年 | 1698篇 |
2006年 | 1658篇 |
2005年 | 1578篇 |
2004年 | 1434篇 |
2003年 | 1259篇 |
2002年 | 1117篇 |
2001年 | 1025篇 |
2000年 | 892篇 |
1999年 | 715篇 |
1998年 | 628篇 |
1997年 | 559篇 |
1996年 | 511篇 |
1995年 | 563篇 |
1994年 | 593篇 |
1993年 | 414篇 |
1992年 | 433篇 |
1991年 | 326篇 |
1990年 | 305篇 |
1989年 | 252篇 |
1988年 | 223篇 |
1987年 | 142篇 |
1986年 | 155篇 |
1985年 | 198篇 |
1984年 | 162篇 |
1983年 | 65篇 |
1982年 | 85篇 |
1981年 | 93篇 |
1980年 | 87篇 |
1979年 | 66篇 |
1978年 | 56篇 |
1977年 | 34篇 |
1976年 | 35篇 |
1975年 | 9篇 |
1973年 | 7篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
42.
目的 比较DNA倍体分析联合人乳头瘤病毒(HPV)与液基细胞学检测(TCT)对早期宫颈癌筛查的敏感性和特异性,探讨DNA倍体分析在宫颈病变筛查中的临床价值。方法 选取2018年上海市浦东新区妇幼保健院进行宫颈癌筛查的患者,先进行DNA倍体分析;发现异常后再进行TCT、HPV联合检测,并分别与宫颈病变的活检病理符合率相比较。结果 共完成9850例宫颈标本的DNA倍体检查,检查异常者有1306例,经TCT检测及HPV联合检测后临床共完成阴道镜检查并活检送病理者968例。DNA倍体分析异常并行活检的正常宫颈组织、低度鳞状上皮内病变(LSIL)、高度鳞状上皮内病变(HSIL)、宫颈癌的比例分别为35.5%(344/968)、44.7%(433/968)、18.2%(176/968)、1.5%(15/968)。DNA倍体异常细胞≥3个组的LSIL及以上的检出率为81.8%(432/528),与TCT对LSIL及以上的检出率(83.5%,685/701)比较,差异无统计学意义(P>0.05)。单独DNA倍体异常细胞≥3个组的灵敏度为69.2%(432/624),联合HPV DNA检查后对LSIL及以上的检出率提高到95.8%(183/191),两组比较有统计学差异(P<0.05),而特异度变化无差异(P>0.05)。结论 DNA倍体联合HPV检测,在特异度基本不变的情况下能够提高宫颈病变筛查的灵敏度,值得临床推广。 相似文献
43.
Yoshiyuki Yamamoto Motohide Uemura Masashi Fujita Kazuhiro Maejima Yoko Koh Makoto Matsushita Kosuke Nakano Yujiro Hayashi Cong Wang Yu Ishizuya Toshiro Kinouchi Takuji Hayashi Kyosuke Matsuzaki Kentaro Jingushi Taigo Kato Atsunari Kawashima Takeshi Ujike Akira Nagahara Kazutoshi Fujita Ryoichi Imamura Hidewaki Nakagawa Norio Nonomura 《Cancer science》2019,110(2):617-628
Reliable biomarkers for renal cell carcinoma (RCC) have yet to be determined. Circulating tumor DNA (ctDNA) is an emerging resource to detect and monitor molecular characteristics of various tumors. The present study aims to clarify the clinical utility of ctDNA for RCC. Fifty‐three patients histologically diagnosed with clear cell RCC were enrolled. Targeted sequencing was carried out using plasma cell‐free DNA (cfDNA) and tumor DNA. We applied droplet digital PCR (ddPCR) to validate detected mutations. cfDNA fragment size was also evaluated using a microfluidics‐based platform and sequencing. Proportion of cfDNA fragments was defined as the ratio of small (50‐166 bp) to large (167‐250 bp) cfDNA fragments. Association of mutant allele frequency of ctDNA with clinical course was analyzed. Prognostic potential was evaluated using log‐rank test. A total of 38 mutations across 16 (30%) patients were identified from cfDNA, including mutations in TP53 (n = 6) and VHL (n = 5), and median mutant allele frequency of ctDNA was 10%. We designed specific ddPCR probes for 11 mutations and detected the same mutations in both cfDNA and tumor DNA. Positive ctDNA was significantly associated with a higher proportion of cfDNA fragments (P = .033), indicating RCC patients with ctDNA had shorter fragment sizes of cfDNA. Interestingly, the changes of mutant allele frequency in ctDNA concurrently correlated with clinical course. Positive ctDNA and fragmentation of cfDNA were significantly associated with poor cancer‐specific survival (P < .001, P = .011). In conclusion, our study shows the clinical utility of ctDNA status and cfDNA fragment size as biomarkers for prognosis and disease monitoring in RCC. 相似文献
44.
Hee Sung KimJong Won KimIn Gyu HwangHye Seung LeeWoo Ho Kim 《Asian Pacific journal of cancer prevention》2019,20(5):1369-1376
Background: Early-onset or familial gastric cancer (GC) is known to have clinicopathologic profiles different fromthose of sporadic GC. We aimed to compare DNA damage response marker expression between early-onset or familialGC and sporadic GC. Methods: GC samples were obtained from patients who underwent gastrectomy for GC at SeoulNational University Hospital. Immunohistochemical analyses of various DNA damage response markers, includingBRCA1, BRCA2, MRE11, RAD51C, and γH2AX, were performed using 54 early-onset GC, 59 familial GC, and 337sporadic GC tissue microarray samples. Correlations between marker expression and clinicopathologic features wereevaluated by univariate and multivariate analyses, and overall survival was analyzed. Results: The rate of γH2AXpositivity was significantly higher (p < 0.001) in early-onset or familial GC than in sporadic GC. In contrast, the rates ofMRE11 negativity and RAD51C negativity were significantly higher in sporadic GC than in early-onset or familial GC.BRCA1 negativity was associated with decreased overall survival in sporadic GC (p = 0.002), and MRE11 negativitywas associated with decreased overall survival in sporadic GC (p = 0.012). Conclusion: Our results show significantdifferences in DNA damage response marker expression between early-onset or familial GC and sporadic GC. 相似文献
45.
46.
目的研究替诺昔康与小牛胸腺DNA(ct DNA)之间的相互作用。方法借助紫外光谱和荧光光谱考察了替诺昔康与ct DNA之间的相互作用,同时通过热变性研究、黏度法试验考察了替诺昔康与ct DNA的相互作用模式。结果 ct DNA加入使替诺昔康紫外光谱出现轻微减色效应,且随着ct DNA浓度的增大,减色效应变强;替诺昔康的加入使ct DNA-盐酸小檗碱发生荧光猝灭,且其猝灭程度具有浓度相关性。替诺昔康对于ctDNA溶液的黏度和热变性温度影响不大。结论替诺昔康与ct DNA是以沟槽方式结合,并且替诺昔康可以使ct DNA-盐酸小檗碱发生静态荧光猝灭。 相似文献
47.
48.
Prediagnosis aspirin use,DNA methylation,and mortality after breast cancer: A population-based study
49.
50.
Guru Sonpavde MD Neeraj Agarwal MD Gregory Russell Pond PhD Rebecca J. Nagy MSc Roberto H. Nussenzveig PhD Andrew W. Hahn MD Oliver Sartor MD Theodore Stewart Gourdin MD Lakshminarayanan Nandagopal MD Elisa M. Ledet PhD Gurudatta Naik MPH Andrew J. Armstrong MD MSc Jue Wang MD Mehmet Asim Bilen MD Shilpa Gupta MD Petros Grivas MD PhD Sumanta K. Pal MD Richard B. Lanman MD AmirAli Talasaz PhD Michael B. Lilly MD 《Cancer》2019,125(9):1459-1469